Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director | December 08, 2017 | December 12, 2017 |
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director | June 18, 2026 | June 23, 2026 |
| Evommune, Inc.EVMN · Entity 5539 | Director | July 07, 2026 | July 09, 2026 |
| Liquidia CorpLQDA · Entity 1860 | Director | June 16, 2026 | June 18, 2026 |
| Liquidia Technologies IncLQDA · Entity 145051 | Director | June 22, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aralez Pharmaceuticals Inc.
Report date December 08, 2017 · Filed December 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 271,609 |
Reported balance
After 2017-12-08 transaction · row 1
1 source rowRow 1 · 2017-12-08 · Purchase · Acquired 50,000 · Balance 271,609 F1: This transaction was executed in multiple trades at prices ranging from $1.4450 to $1.4890. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy Trust | 5,000 |
Reported balance
Holding disclosure · report date 2017-12-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: The shares are held by the Laura A. Kirsch Trust, dated 4/12/2000 (the "Trust"), of which the Reporting Person is a trustee. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the Issuer's securities held by the Trust are reported herein, and the Reporting Person expressly disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.4450 to $1.4890. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The shares are held by the Laura A. Kirsch Trust, dated 4/12/2000 (the "Trust"), of which the Reporting Person is a trustee. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the Issuer's securities held by the Trust are reported herein, and the Reporting Person expressly disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein.
Atea Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,700 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17 | Direct | 37,700 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700 F3: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F3: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
Evommune, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 10,000 |
Reported balance
After 2026-07-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-07 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Liquidia Corp
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,637 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 46,637 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
Liquidia Technologies Inc
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.97 · Expires 2030-06-22 | Direct | 20,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests in 36 equal monthly installments, becoming fully vested on June 22, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 36 equal monthly installments, becoming fully vested on June 22, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 64,103 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 85,034 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 96,975 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | PurchaseCommon Stock | 10,000 | $13.30 | $133,000.00 |
DisclosureSEC source: 0001290976-26-000004 · primarydocument.xml · nonDerivative · entry 1 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 37,700 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001193125-26-279717 · ownership.xml · derivative · entry 2 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,700 Underlying: Common Stock · 37,700 shares Expires 2036-06-17 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279717 · ownership.xml · derivative · entry 1 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 5,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075783 · tm2618309-2_4seq1.xml · nonDerivative · entry 1 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,637 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 20:30 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 10,000 | $54.80 | $548,000.00 |
DisclosureSEC source: 0001104659-26-070121 · tm2616844-1_4seq1.xml · nonDerivative · entry 4 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Through Revocable Trust of Arthur S. Kirsch Disclosed balance after: 0 Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 00:03 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantStock Option (Right to buy) · Derivative | 15,673 | $0.00 Strike: $19.82 | $0.00 |
DisclosureSEC source: 0001290976-26-000002 · primarydocument.xml · derivative · entry 1 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,673 Underlying: Common Stock · 15,673 shares Expires 2036-06-01 F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:30 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 5,000 | $56.00 | $280,000.00 |
DisclosureSEC source: 0001104659-26-070121 · tm2616844-1_4seq1.xml · nonDerivative · entry 3 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Through Revocable Trust of Arthur S. Kirsch Disclosed balance after: 10,000 Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 15,000 | $60.22 | $903,300.00 |
DisclosureSEC source: 0001104659-26-070121 · tm2616844-1_4seq1.xml · nonDerivative · entry 2 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Through Revocable Trust of Arthur S. Kirsch Disclosed balance after: 15,000 F1 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $59.90 to $60.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:15 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantStock Option (Right to Buy) · Derivative | 37,960 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001290976-25-000010 · form4-11072025_041112.xml · derivative · entry 1 KIRSCH ARTHUR S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,960 Underlying: Common Stock · 37,960 shares Expires 2035-11-04 F1 · derivative.exercise_date: One third (1/3) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 18,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061190 · tm2518541-4_4seq1.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,755 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:52 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 164,800 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000950170-25-025901 · ownership.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,800 Underlying: Common Stock · 164,800 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six (36) equal monthly installments following February 20, 2025 such that the option is fully vested on February 20, 2028. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 01:38 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 20,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-074472 · tm2418154-5_4seq1.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,359 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 21:00 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001104659-23-073391 · tm2317720-5_4seq1.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-19 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 19, 2026. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:33 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001104659-22-073534 · tm2219055-7_4seq1.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 17, 2025. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:16 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock | 30,000 | $4.24 | $127,200.00 |
DisclosureSEC source: 0001104659-21-138087 · tm2132597-2_4seq1.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:40 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 96,975 | $5.92 Strike: $3.58 | $574,092.00 |
DisclosureSEC source: 0001104659-21-136408 · tm2131118-8_4seq1.xml · derivative · entry 5 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 96,975 shares Expires 2031-05-12 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:40 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 85,034 | $5.06 Strike: $4.44 | $430,272.04 |
DisclosureSEC source: 0001104659-21-136408 · tm2131118-8_4seq1.xml · derivative · entry 4 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 85,034 shares Expires 2030-05-13 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:40 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $7.21 Strike: $2.29 | $721,000.00 |
DisclosureSEC source: 0001104659-21-136408 · tm2131118-8_4seq1.xml · derivative · entry 3 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:40 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 64,103 | $7.21 Strike: $2.29 | $462,182.63 |
DisclosureSEC source: 0001104659-21-136408 · tm2131118-8_4seq1.xml · derivative · entry 2 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 64,103 shares Expires 2029-05-15 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 22:40 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerCommon Stock | 30,000 | $9.50 | $285,000.00 |
DisclosureSEC source: 0001104659-21-136408 · tm2131118-8_4seq1.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:22 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112104 · tm2126786-5_4seq1.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:06 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantCommon stock | 10,000 | $3.70 | $36,950.00 |
DisclosureSEC source: 0001593968-21-001331 · primary_01.xml · nonDerivative · entry 2 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:06 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantCommon stock | 20,000 | $3.58 | $71,600.00 |
DisclosureSEC source: 0001593968-21-001331 · primary_01.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:11 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 96,975 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001593968-21-001312 · primary_01.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,975 Underlying: Common stock · 96,975 shares Expires 2031-05-12 F1 · derivative.exercise_date: The stock option vests in full on the first anniversary of the grant date, or May 12, 2022 Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:06 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,390 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001104659-21-042431 · tm2111007-4_4seq1.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,390 Underlying: Common Stock · 41,390 shares Expires 2031-03-24 F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:30 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.97 | $0.00 |
DisclosureSEC source: 0001104659-20-076076 · a4.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments, becoming fully vested on June 22, 2023. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:21 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 85,034 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001593968-20-001171 · primary_01.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,034 Underlying: Common stock, $0.001 par value · 85,034 shares Expires 2030-05-13 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 13, 2021. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:30 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantNonqualified Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001104659-19-048448 · a4.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-08-29 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments, becoming fully vested on May 8, 2022. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:54 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $2.29 Strike: $2.29 | $229,000.00 |
DisclosureSEC source: 0001593968-19-001127 · primary_01.xml · derivative · entry 2 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,103 Underlying: Common stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F3 · derivative.exercise_date: The stock option becomes vested and exercisable on May 15, 2020. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:54 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 64,103 | $2.29 Strike: $2.29 | $146,795.87 |
DisclosureSEC source: 0001593968-19-001127 · primary_01.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common stock, $0.001 par value · 64,103 shares Expires 2029-05-15 F1 · derivative.exercise_date: The option becomes vested and exercisable in three equal annual installments over three years from May 15, 2019, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 21:06 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | PurchaseCommon Stock | 895 | $18.50 | $16,557.50 |
DisclosureSEC source: 0001104659-18-068771 · a4.xml · nonDerivative · entry 2 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:06 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | PurchaseCommon Stock | 105 | $18.00 | $1,890.00 |
DisclosureSEC source: 0001104659-18-068771 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105 Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:07 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | PurchaseCommon Stock | 1,000 | $18.25 | $18,250.00 |
DisclosureSEC source: 0001104659-18-067907 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:03 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantStock Option · Derivative | 10,050 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047757 · a4.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,050 Underlying: Common Stock · 10,050 shares Expires 2028-07-25 F1 · derivative.exercise_date: 2.778% of such stock options vest on August 25, 2018 and on such date every month thereafter, through the third anniversary of August 25, 2018, subject to Mr. Kirsch's continuous service as of each such date. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 12:00 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 50,000 | $1.47 | $73,535.00 |
DisclosureSEC source: 0001104659-17-072830 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,609 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.4450 to $1.4890. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 11:00 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 15,000 | $1.15 | $17,181.00 |
DisclosureSEC source: 0001104659-17-040029 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,609 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.1375 to $1.1499. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 11:01 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 50,000 | $1.17 | $58,525.00 |
DisclosureSEC source: 0001104659-17-039685 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,609 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.1483 to $1.1900. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032408 · a4.xml · derivative · entry 3 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, without par value · 15,000 shares Expires 2027-05-11 F4 · derivative.exercise_date: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032408 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,609 F1 · kind: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. F2 · balance_after: Includes 149,109 shares of Common Stock and 7,500 Restricted Stock Units. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:16 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 45,000 | $2.27 | $102,249.00 |
DisclosureSEC source: 0001104659-17-017607 · a4.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,109 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.11 to $2.53. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.